Skip to main content

Table 3 Time Course of Parameters after BAV in the Non-MR Group

From: Mid-term effect of balloon aortic valvuloplasty on mitral regurgitation in aortic stenosis

 Baseline1 month after BAVP value3 months after BAVP value
Clinical data
 NYHA III/IV, n (%)19 (44.2)2 (4.5)< 0.0012 (4.5)< 0.001
Laboratory data
 BNP, pg/mL216 (112–422)201 (103–405)0.293171 (11–368)0.086
Conventional echo parameters
 LVEDD, mm43.2 ± 7.142.8 ± 6.40.68042.8 ± 6.40.659
 LVESD, mm28.9 ± 7.028.0 ± 6.90.23027.4 ± 5.80.091
 LVEF, %58.6 ± 7.859.8 ± 8.80.31861.4 ± 7.80.024
 LVSVI, mL44.7 ± 13.249.0 ± 13.50.01649.3 ± 14.70.009
 E/A0.7 (0.5–0.9)0.7 (0.5–0.9)0.4350.7 (0.5–0.8)0.610
 E/e’17.8 ± 7.817.5 ± 8.20.69218.0 ± 9.90.918
 TR-PG, mmHg33.4 ± 12.131.2 ± 13.50.13830.6 ± 11.40.151
 AR ≥ moderate, n (%)3 (7.0)4 (9.5)0.7136 (14.0)0.483
AS parameters
 AVA, cm20.70 ± 0.150.88 ± 0.20< 0.0010.84 ± 0.20< 0.001
 AVAi, cm2/m20.48 ± 0.100.62 ± 0.14< 0.0010.59 ± 0.13< 0.001
 Peak V, m/s69.1 ± 27.053.1 ± 23.1< 0.00157.0 ± 23.80.001
 mPG (mmHg)39.1 ± 15.630.9 ± 14.2< 0.00132.5 ± 14.3< 0.001
MR parameters
 MR jet area, cm21.0 (0.3–2.5)0.7 (0.2–1.8)0.6270.9 (0.3–2.1)0.943
 %MR, %7.3 (2.0–12.9)4.9 (1.2–11.3)0.4724.1 (1.7–12.2)0.801
 Mitral annular dimension, mm25.8 ± 3.123.8 ± 3.40.00124.7 ± 3.30.074
 Tenting height, mm3.6 ± 1.63.0 ± 1.50.0473.0 ± 1.70.052
 Tenting area, mm246.9 ± 24.036.5 ± 21.10.01537.9 ± 25.90.052
  1. Data are mean ± SD for normally distributed data and median and interquartile range for non-normally distributed data, or n (%)
  2. Abbreviations as in Table 1